222 related articles for article (PubMed ID: 32381458)
1. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
Froehner M; Koch R; Thomas C
Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
[No Abstract] [Full Text] [Related]
2. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol 2020;77:675-82.
Mai Z; Yuan R
Eur Urol; 2020 Sep; 78(3):e133-e134. PubMed ID: 32444263
[No Abstract] [Full Text] [Related]
3. Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041.
Orczyk C; Marsden T; Emberton M
Eur Urol; 2021 Mar; 79(3):e98-e99. PubMed ID: 33341284
[No Abstract] [Full Text] [Related]
4. Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Du J; Liu Y; Yan W
Eur Urol; 2020 Aug; 78(2):e64. PubMed ID: 32362499
[No Abstract] [Full Text] [Related]
5. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Chesnut GT; Vertosick EA; Ehdaie B
Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
[No Abstract] [Full Text] [Related]
6. Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015.
Cimadamore A; Lopez-Beltran A; Cheng L; Montironi R
Eur Urol; 2023 Mar; 83(3):e84-e86. PubMed ID: 36517350
[No Abstract] [Full Text] [Related]
7. Re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055: Standardized Reporting for Economic Analyses Should be Mandatory.
Castillo-Jimenez DA; García-Perdomo HA
Eur Urol; 2019 Jul; 76(1):e9. PubMed ID: 30665813
[No Abstract] [Full Text] [Related]
8. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.
Ayubi E; Safiri S
Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506
[No Abstract] [Full Text] [Related]
9. Reply to Diana A. Castillo-Jimenez and Herney A. García-Perdomo's Letter to the Editor re: Niranjan J. Sathianathen, Badrinath R. Konety, Fernando Alarid-Escudero, Nathan Lawrentschuk, Damien M. Bolton, Karen M. Kuntz. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.055. Standardized Reporting for Economic Analyses Should be Mandatory.
Sathianathen NJ; Konety BR
Eur Urol; 2019 Jul; 76(1):e10-e11. PubMed ID: 30665809
[No Abstract] [Full Text] [Related]
10. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764.
Scott E; Mamawala M; Epstein JI; Landis P; Wolf S; Trock ; Carter HB
Urol Oncol; 2017 Mar; 35(3):121-122. PubMed ID: 28159497
[TBL] [Abstract][Full Text] [Related]
11. Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003.
Wang Z; Zhao Y; Zhang Y
Eur Urol; 2022 May; 81(5):e120. PubMed ID: 35232603
[No Abstract] [Full Text] [Related]
12. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
Trock BJ; Karnes RJ
Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
[No Abstract] [Full Text] [Related]
13. Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002.
Gandaglia G; Barletta F; Briganti A; Montorsi F
Eur Urol Focus; 2024 Jan; 10(1):205. PubMed ID: 37455217
[No Abstract] [Full Text] [Related]
14. Re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
Yan W; Zhou Z; Li H
Eur Urol; 2017 Jan; 71(1):e12. PubMed ID: 27262630
[No Abstract] [Full Text] [Related]
15. Re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.02.002.
Ates F; Akyol I; Soydan H
Eur Urol; 2012 Jul; 62(1):e9; author reply e10-1. PubMed ID: 22512903
[No Abstract] [Full Text] [Related]
16. Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.031.
Montorsi F; Bravi CA; Gandaglia G; Mottrie A; Briganti A
Eur Urol; 2022 Nov; 82(5):e148. PubMed ID: 36064476
[No Abstract] [Full Text] [Related]
17. Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009.
van den Bergh RCN; Valerio M; Tilki D; Gandaglia G;
Eur Urol; 2020 Aug; 78(2):e67-e68. PubMed ID: 32303383
[No Abstract] [Full Text] [Related]
18. Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
Kim SE; Shin JI; Shoag JE
Eur Urol; 2021 Jul; 80(1):e14. PubMed ID: 33941402
[No Abstract] [Full Text] [Related]
19. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
Wei Y; Ye D; Zhu Y
Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186
[No Abstract] [Full Text] [Related]
20. Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Cimadamore A; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R
Eur Urol; 2021 Sep; 80(3):e81-e82. PubMed ID: 34148712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
